Why this matters 1 Efficacy arms race in obesity Zepbound previously showed superior outcomes Wegovy 7.2 mg narrows the gap Competition now driven by clinical performance 2 Massive market at stake Obesity = one of the largest pharma markets globally Prescriber preference shifting toward higher efficacy Market share highly sensitive to outcomes 3 Faster FDA pathway signal First GLP-1 approved under FDAs national priority voucher program Accelerated review (12 months) 4 Global rollout underway EU/UK approvals already in place (7.2 mg) U.S
Testosterone and Metabolic Syndrome: A Meta-Analysis Study
Previous reviews ( Therefore, the purpose of this review is to synthesize and contextualize the evidence that links taste perception and gut-derived peptides, with a particular focus on the emerging role of GLP-1 as both a metabolic hormone and a neurosensory modulator
Intellias NTLA-2001, being developed along with partner Regeneron for the genetic liver disease transthyretin (ATTR) amyloidosis cardiomyopathy, is expected to enter Phase III by the end of this year, Intellia announced
6E), Allobaculum , Lactobacillus , Bacteroides , Oscillospira , Helicobacter , Adlercreutzia , Akkermansia , and Bifidobacterium were most abundant
2021;10:e021934
